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                                                      Highlights
 Cardiac toxicity of tacrolimus is rare, less known but can be serious.
 Tacrolimus cardiotoxicity should be suspected in unexplained 
cardiomyopathy post kidney transplant.
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Abstract
The objective of immunosuppressive drugs used in solid-organ transplantation is to achieve acceptable 
rejection rates, minimise infections, prolong graft and patient survival. Cardio vascular disease is a 
major cause of death in kidney transplant recipients. The drugs commonly used to prevent rejection 
(Calcineurin inhibitors-CNIs and steroids) contribute to cardiac disease seen in transplant patients by 
increasing the risk of hypertension and diabetes. Direct cardiac toxicity of chemotherapeutic drugs such 
as Doxorubicin is well-known but potential direct effect of CNIs on myocardium is less explored and 
understood. Cardiac toxicity, a rare serious adverse effect of Tacrolimus has been observed in patients 
receiving solid organ transplant such as liver, bowel and kidney. In this report, we describe a case of 
new onset severe dilated cardiomyopathy after kidney transplantation.  Reversal of heart failure 
occurred after Tacrolimus discontinuation and switch to a mammalian Target of Rapamycin (mTOR) 
inhibitor; Sirolimus. 
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Introduction
Cardio vascular disease contributes significantly to mortality and morbidity after kidney transplantation. 
The main contributors are hypertension, diabetes, dyslipidaemia and poor kidney function at least in 
part driven by the immunosuppressive drugs such as CNIs and corticosteroids.  Tacrolimus is a 
calcineurin inhibitor commonly used post solid organ transplant. It is proven to be superior to 
Ciclosporine A in improving graft survival and preventing acute rejection in liver and kidney transplants 
[1].Tacrolimus is better tolerated and is currently the mainstay of immunosuppressive regimes in kidney 
and other solid organ transplantation. Potential direct toxic effect of CNIs on myocardium is not well 
studied. Previous reports have predominantly described concentric and hypertrophic cardiomyopathy 
following solid organ transplant [2, 3]. Mc Leod et al reported a case of dilated cardiomyopathy 
following liver transplant which did not recover following Tacrolimus withdrawal[4]. In this report, we 
describe a kidney transplant patient who developed a severe life- threatening dilated cardiomyopathy 
on Tacrolimus, which reversed after discontinuation of the drug and switch to mTOR inhibitor 
Sirolimus.
Case presentation
We present the case of a 66-year-old female patient of Nigerian origin with a background of asthma, 
osteoarthritis, chronic subdural haemorrhage, microcytic anaemia and end stage renal failure secondary 
to hypertensive nephropathy, on intermittent unit-based haemodialysis (x 3 times/week) from 2011-
2018. Usual medications included Aspirin, Candesartan, Alfacalcidol and Furosemide. Her baseline 
ECG met the Sokolow-Lyon criteria for left ventricular hypertrophy. PR interval was138ms, QRS 
duration 94ms and QTc 390ms. Transthoracic echocardiogram in September 2016 before renal 
transplant showed normal left ventricular (LV) size with mildly impaired systolic function and EF was 
estimated as 50-55%. Right ventriclular systolic function was normal. The left atrium was mildly dilated 
and there was no significant valvular disease. The estimated pulmonary pressure was 24mmHg.  LV 
end diastolic diameter was 3.9 cm and end systolic diameter was 3 cm. LV out flow tract diameter was 
2.1cm and ejection fraction (EF) was measured as 50-55%.
The patient received a deceased donor kidney transplant in August 2017. Surgery was uneventful with 
immediate graft function and her Creatinine came down to 80-100 umol/L with eGFR of 51-60 
ml/min/1.73m2. She received our low immunological risk immunosuppression protocol with 
Basiliximab induction, Mycophenolate Mofetil 1 gram twice a day, Tacrolimus 9 mg twice a day 
(0.1mg/kg BD) and prednisolone 20mg OD (stopped on D7). Tacrolimus levels were initially high. The 
dose was progressively reduced to achieve a target concentration of 8-12micg/l (first 3m) and 6-8 micg/l 
(after 3m). The patient was discharged on day five post-transplant, well in herself with no symptoms or 
signs of cardiac failure. She was under regular transplant clinic follow up with good and stable kidney 
function (Creatinine 110-130 micmol/l, eGFR 50-60), well controlled blood pressure, normal glucose 
and HbA1C levels.
In January 2018 the patient presented with symptoms and signs of decompensated heart failure 
including exertional dyspnoea, orthopnoea and pitting oedema. She was in pulmonary oedema needing 
admission for intravenous diuretics. Echocardiogram performed in January 2018 showed a dilated LV 
with severe global LV dysfunction, the EF had declined to 20-25%, severe decline compared to her pre 
transplant echocardiogram. She had no angina and no evidence of pericarditis. Due to the rapidity of 
onset of her heart failure, she was thought to have viral myocarditis. A panel of serologies and viral 
PCRs were performed to look for any infective cause. All the tests were negative including negative 
CMV, EBV PCRs, negative Lyme, HTLV, HIV and Rickettsia serologies. We considered the adverse 
impact of her AV fistula on cardiac function and ligated this in March 2018. There was no improvement 
in her cardiac function following this procedure. She remained short of breath on minimal exertion, 
NYHA class 3/4 in spite of being on maximum tolerated doses of loop diuretic, Spironolactone and 
Ramipril. Tacrolimus levels were within the target range of 5-8 mcg/l. The deterioration progressed and 
by April 2018 the transthoracic echocardiogram showed a dilated left ventricle (mildly dilated by 
diameter and severely dilated by volume- modified biplane; end-diastolic volume of 135 ml), (Figure 
1) with severely impaired global systolic function and an LVEF of 11% by modified Simpson's biplane 
method. There was evidence of restrictive filling pattern of the left ventricle (E/A: 2.16, E/E' average: 
19.31). There was no evidence of LV hypertrophy or thrombus (End- diastolic dimension: 5.4 cm, end-
systolic dimension: 4.9 cm).  LV septum wall diastolic thickness was 1.01 cm and LV posterior wall 
diastolic thickness was 1.19 cm. The right ventricle (RV) was basally dilated and had impaired systolic 
function. There was evidence of mild mitral regurgitation and the estimated pulmonary systolic pressure 
was 20-25mmHg. At this point she underwent further investigations in search for cause of heart failure; 
including a coronary angiogram which showed calcified unobstructed coronaries and a cardiac MRI 
scan which showed a severely dilated LV cavity with severe global LV systolic impairment (EF 17%), 
mildly dilated RV cavity with moderate RV systolic impairment (EF 34%) and a severely dilated LA. 
There was no evidence of thrombus, fibrosis or infarction. LV end-diastolic volume: 252 ml (82-162) 
and LV end-systolic volume: 207 ml (20-57), (Figure 2). LV mass was estimated as 140 g (73-145). 
The findings were consistent with a non-ischemic dilated cardiomyopathy. The patient had a repeat 
autoimmune and viral screen for dilated cardiomyopathy, which were all negative. She was started on 
Bisoprolol, Candesartan and Spironolactone and was discharged home on 80 and 40 mg twice daily 
dose of Furosemide. After ruling out all other potential causes of heart failure, we agreed that 
Tacrolimus induced cardiomyopathy was the most likely explanation.  Following multidisciplinary 
discussions between the renal and cardiology teams we decided to withdraw Tacrolimus and switched 
to Sirolimus. The Sirolimus was started at a dose of 2mg OD and titrated to achieve a target level of 5-7 
ng/ml.
In June 2018 patient was reviewed at cardiology outpatient clinic and a steady recovery was noted at 
that point. It was also noted that her NT-pro-BNP fell from 16,124ng/L on 15 April to 4869ng/L by 23rd 
of May 2018. On physical examination she only had mild pitting oedema up her shins. Transthoracic 
echocardiogram showed some subtle improvements; Dilated left ventricle (end-diastolic dimension: 5 
cm from 5.4 cm, end-systolic dimension: 4 cm from 4.9 cm in April 2018) with global severely impaired 
systolic function with estimated LVEF of 15-20%. The RV was less dilated and RV longitudinal 
function has slightly improved. Estimated pulmonary artery systolic pressure was 30 mmHg. There had 
also been significant improvement in the filling pattern and the deceleration time had increased from 
131 to 285ms. As a result, sirolimus was continued.
In March 2019, as part of her regular follow up and nine months after discontinuation of tacrolimus and 
introduction of sirolimus, the patient had a repeat transthoracic echocardiogram, which showed normal 
LV cavity size (2.94 cm/m²; 39mL/m²) with mildly increased wall thickness. Overall systolic function 
appeared was only mild to moderately impaired with reduced longitudinal function, and EF was 
measured by Simpson's Biplane was 49%, LV end-diastolic dimension was 5 cm, end-systolic 
dimension was 3.5 cm and LVOT diameter was 2.1 cm (Figure 3). The right ventricle had normal 
dimension and systolic function. The echocardiographic findings at various time points are summarised 
in table 1. Renal function was stable with Creatinine of 100 umol/L, eGFR was 45 ml/min/1.73m2. 
Abdominal ultrasound scan did not show any abnormalities. There were no episodes of rejection 
following the switch to Sirolimus.  On her latest follow up in September 2019, she has remained well 
with minimal shortness of breath on exertion, mild pedal oedema and stable renal allograft function. 
She has had no further hospital admissions for heart failure.
Discussion
Tacrolimus is a potent immunosuppressant drug which has transformed the outcome of solid organ 
transplants. It has adverse renal, central nervous system and vascular side effects which have been 
previously documented. The cardiotoxic effects of Tacrolimus are uncommon and have been most 
commonly characterized as obstructive or concentric hypertrophic cardiomyopathy described following 
liver, bowel, renal and heart transplants [2] [3, 5]. McLeod et al described development of cardiac 
hypertrophy shortly after the introduction of Tacrolimus, particularly involving the intraventricular 
septum, which then rapidly progressed to a dilated cardiomyopathy[4]. In these reports, Tacrolimus 
withdrawal either had no effect on cardiac function or there was some improvement.  Withdrawal of 
Tacrolimus and switching to an alternative immunosuppressant requires careful consideration of 
comorbidities, side effect profile and potential risk of rejection. Replacing CNI with an mTOR inhibitor 
(Sirolimus or Everolimus) is an option to reduce nephrotoxicirty and minimise cardiovascular risks but 
concerns over efficacy and tolerability has limited their use in clinical practice. However, the recent 
evidence does support the use of these drugs along with low dose tacrolimus[6] .
The mechanism of Tacrolimus cardiac toxicity has not been fully understood. It is suspected that 
calcineurin inhibition can alter sympathetic activation or potentially influence calcium release channels, 
contributing to the development of neurotoxicity, nephrotoxicity, and cardiac toxicity[7]. Indirect 
effects on heart through hypertension and diabetes (The risk of both are increased by tacrolimus) 
contribute to cardiac dysfunction. 
Presentation with cardiomyopathy in previous reports occurred between one week and seven years. The 
majority of Tacrolimus trough concentrations were > 10 ng/mL (range 5–64.4 ng/mL). In general, 
higher Tacrolimus trough levels were associated with a quicker onset of cardiomyopathy. Modern 
immunosuppressive regimes, including our protocol; tend to run lower levels, particularly 3 months 
post transplantation. In our patient apart from few high levels initially, majority of subsequent levels 
including levels at the time of presentation with heart failure were within target range. Although 
screening for infectious causes of myocarditis were negative, we cannot totally rule out a possibility of 
viral myocarditis that recovered upon Sirolimus switch as Sirolimus is known to have anti- viral 
properties. The presentation with severe heart failure we are reporting here is a rare clinical problem as 
the majority of patients on Tacrolimus do well. However, direct toxicity of this drug in contributing to 
cardiac dysfunction following kidney transplantation and the effect of mTOR inhibitors on cardiac 
structure and function need evaluation in future studies. Our patient made excellent recovery upon 
sirolimus switch and we could find only one other case report in the literature describing use of 
Sirolimus for paediatric transplant patients with Tacrolimus induced hypertrophic cardiomyopathy[8]. 
As far as we are aware, ours is the first report of Tacrolimus induced dilated cardiomyopathy which 
resolved upon Sirolimus switch.
In conclusion, our case demonstrates an adult renal allograft recipient who developed a dilated 
cardiomyopathy following kidney transplantation whilst on Tacrolimus therapy. Almost full recovery 
was achieved by conversion from Tacrolimus to Sirolimus. High index of suspicion is required in 
patients with new diagnosis of heart failure and worsening of existing heart failure after being treated 
with Tacrolimus. If tacrolimus cardiotoxicity is suspected multidisciplinary discussions are needed to 
decide the best available alternatives and to monitor response to the intervention.
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Figures
Figure 1: Four-chamber view on 2D transthoracic echocardiogram showing aneurysmal dilation of the 
left ventricular mid/apical segments, in end-diastole of cardiac cycle, patient was on Tacrolimus. 
Ejection fraction by Simpson’s biplane method 11%.
Figure 2: Four-chamber view on late gadolinium enhancement (LGE) cardiac MRI; showing a severely 
dilated left ventricle, and dilated atria. No myocardial enhancement is seen and the appearances are 
compatible with a dilated cardiomyopathy.  
Figure 3: Two-chamber view on 2D transthoracic echocardiogram in end-systole; patient left ventricle 
has remodeled significantly with reduction in LV and RV volume, and decreased size of atria after 
discontinuation of Tacrolimus and switch to Sirolimus.   Ejection fraction by Simpson’s biplane method 
49%.
Table 1: Echocardiographic findings and NT-pro-BNP before transplantation, at presentation with heart 























EF 50-55% 20-25% 11% 15-20% 49%
LV end diastolic 
diameter
3.9 cm 5.4 cm 5 cm 5 cm
LV end systolic 
diameter
3 cm 4.9 cm 4 cm 3.1 cm
LV outflow tract 
diameter
2.1 cm 2.1 cm
NT-pro-BNP 16,124ng/L 4869ng/L
